Polyethylenimine Hybrid Thin-Shell Hollow Mesoporous Silica Nanoparticles as Vaccine Self-Adjuvants for Cancer Immunotherapy.,ACS Applied Materials & Interfaces

当前位置： X-MOL 学术 › ACS Appl. Mater. Interfaces › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Polyethylenimine Hybrid Thin-Shell Hollow Mesoporous Silica Nanoparticles as Vaccine Self-Adjuvants for Cancer Immunotherapy.
ACS Applied Materials & Interfaces ( IF 8.3 ) Pub Date : 2019-12-12 , DOI: 10.1021/acsami.9b19446
Qianqian Liu ₁ , Yajie Zhou ₂ , Mo Li ₁ , Liang Zhao ₂ , Jingli Ren ₁ , Danqi Li ₂ , Zhengping Tan ₁ , Ke Wang ₁ , Heli Li ₃ , Mubashir Hussain ₁ , Lianbin Zhang ₁ , Guanxin Shen ₃ , Jintao Zhu ₁ , Juan Tao ₂

Affiliation

Conventional adjuvants (e.g., aluminum) are insufficient to trigger cell-mediated immunity, which plays a crucial role in triggering specific immunity against cancer. Therefore, developing appropriate adjuvants for cancer vaccines is a central way to stimulate the antitumor immune response. Hollow mesoporous silica nanoparticles (HMSNs) have been proven to stimulate Th1 antitumor immunity in vivo and promote immunological memory in the formulation of novel cancer vaccines. Yet, immune response rates of existing HMSNs for anticancer immunity still remain low. Here, we demonstrate the generation of polyethylenimine (PEI)-incorporated thin-shell HMSNs (THMSNs) through a facile PEI etching strategy for cancer immunotherapy. Interestingly, incorporation of PEI and thin-shell hollow structures of THMSNs not only improved the antigen-loading efficacy and sustained drug release profiles but also enhanced the phagocytosis efficiency by dendritic cells (DCs), enabled DC maturation and Th1 immunity, and sustained immunological memory, resulting in the enhancement of the adjuvant effect of THMSNs. Moreover, THMSNs vaccines without significant side effects can significantly reduce the potentiality of tumor growth and metastasis in tumor challenge and rechallenge models, respectively. THMSNs are considered to be promising vehicles and excellent adjuvants for the formulation of cancer vaccines for immunotherapy.

中文翻译：

聚乙烯亚胺杂化薄壳空心中孔二氧化硅纳米粒子作为疫苗自身佐剂的癌症免疫治疗。

常规佐剂（例如铝）不足以触发细胞介导的免疫，这在触发针对癌症的特异性免疫中起着至关重要的作用。因此，开发用于癌症疫苗的合适佐剂是刺激抗肿瘤免疫反应的主要方法。中空二氧化硅纳米粒子（HMSNs）已被证明可以刺激Th1体内抗肿瘤免疫力，并在新型癌症疫苗制剂中促进免疫记忆。但是，现有HMSN对抗癌免疫的免疫应答率仍然很低。在这里，我们证明了通过简便的PEI蚀刻策略进行癌症免疫疗法，可以生成聚乙烯亚胺（PEI）结合的薄壳HMSN（THMSNs）。有趣的是，PEI和THMSNs的薄壳中空结构的结合不仅提高了抗原装载功效和持续的药物释放曲线，而且还增强了树突状细胞（DC）的吞噬作用，实现了DC成熟和Th1免疫力，以及持续的免疫记忆，从而增强THMSNs的佐剂作用。此外，没有明显副作用的THMSNs疫苗可以分别显着降低肿瘤激发和再挑战模型中肿瘤生长和转移的潜力。THMSN被认为是用于免疫疗法的癌症疫苗制剂的有前途的载体和出色的佐剂。导致THMSNs的佐剂作用增强。此外，没有明显副作用的THMSNs疫苗可以分别显着降低肿瘤激发和再挑战模型中肿瘤生长和转移的潜力。THMSN被认为是用于免疫疗法的癌症疫苗制剂的有前途的载体和出色的佐剂。导致THMSNs的佐剂作用增强。此外，没有明显副作用的THMSNs疫苗可以分别显着降低肿瘤激发和再挑战模型中肿瘤生长和转移的潜力。THMSN被认为是用于免疫疗法的癌症疫苗制剂的有前途的载体和出色的佐剂。

更新日期：2019-12-13

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南